Drawing for ANDITROL

USPTO serial 78803433

ANDITROL

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MCCAULEY, BRENDAN D
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ANDITROL?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kathleen Cooney-Porter

KATHLEEN COONEY-PORTER OBLON, SPIVAK, MCCLELLAND, MAIER & NEUST1940 DUKE STALEXANDRIA, VA 22314-3451UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005PHARMACEUTICAL PRODUCTS AND PREPARATIONS, NAMELY, PHARMACEUTICAL PREPARATIONS FOR TESTOSTERONE REPLACEMENT THERAPYACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 3, 2018ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Jul 13, 2009MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 13, 2009ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 12, 2008EX3GSOU EXTENSION 3 GRANTED—
Sep 11, 2008AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Sep 2, 2008EXT3SOU EXTENSION 3 FILED—
Sep 2, 2008MAILPAPER RECEIVED—
Jun 18, 2008EX2GSOU EXTENSION 2 GRANTED—
Jun 9, 2008EXT2SOU EXTENSION 2 FILED—
Jun 9, 2008MAILPAPER RECEIVED—
Sep 25, 2007EX1GSOU EXTENSION 1 GRANTED—
Aug 21, 2007EXT1SOU EXTENSION 1 FILED—
Aug 21, 2007MAILPAPER RECEIVED—
Jun 12, 2007NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 20, 2007PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 28, 2007NPUBNOTICE OF PUBLICATION—
Jan 31, 2007PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 31, 2007CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 24, 2007ACECAMENDMENT FROM APPLICANT ENTERED—
Jan 24, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 24, 2007ALIEASSIGNED TO LIE—
Dec 22, 2006MAILPAPER RECEIVED—
Jun 25, 2006GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 25, 2006CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 22, 2006DOCKASSIGNED TO EXAMINER—
Feb 7, 2006NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance